NAB-Paclitaxel Plus Carboplatin As First-Line Therapy for Patients with Advanced NSCLC in the Real-World Setting: Safety Results of the Non-Interventional Neptun Study

被引：0
|
作者：
Dechow, Tobias [1 ]
Riera-Knorrenschild, Jorge [2 ]
Hackanson, Bjoern [3 ]
von Weikersthal, Ludwig Fischer [4 ]
Chiabudini, Marco [5 ]
Timm, Barbara [5 ]
Zerbes, Ralf Michael [5 ]
Potthoff, Karin [5 ]
机构：
[1] Onkol Hamatol Ravensburg, Ravensburg, Germany
[2] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany
[3] Univ Klinikum Augsburg, Augsburg, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Georgia
[5] IOMEDICO AG, Freiburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
276
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [11] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PREDICTIVE FACTORS
    Hirsh, Vera
    Page, Ray
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S879 - S879
  • [12] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PERIPHERAL NEUROPATHY
    Sakai, Hiroshi
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S569 - S570
  • [13] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): AN ECONOMIC ANALYSIS
    Spigel, David
    Harwin, William
    Dranitsaris, George
    Binder, Gary
    Weber, Paul
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1176 - S1177
  • [14] Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Hawkins, M. J.
    Manikhas, G.
    Makhson, A.
    Cheporov, S.
    Orlov, S.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
  • [16] Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC
    Goldman, J. W.
    Waterhouse, D.
    George, B.
    O'Dwyer, P.
    Chen, T.
    Trunova, N.
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1959 - S1960
  • [17] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [18] Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    Tamiya, Akihiro
    Tamiya, Motohiro
    Inagaki, Yuji
    Taniguchi, Yoshihiko
    Nakao, Keiko
    Matsuda, Yoshinobu
    Kawamura, Takahisa
    Kunimasa, Kei
    Inoue, Takako
    Nishino, Kazumi
    Okishio, Kyoichi
    ANTICANCER RESEARCH, 2023, 43 (03) : 1325 - 1330
  • [19] Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: final results of the non-interventional study NABUCCO
    Potthoff, K.
    Nusch, A.
    Soeling, U.
    Hansen, R.
    Salat, C.
    Grebhardt, S.
    Marschner, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [20] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
12345